The gene editing company raised $108m in its IPO, floating at the top of its range, while Regeneron and Novartis provided $55m through concurrent private placements.
US-based gene editing technology developer Intellia Therapeutics floated on Nasdaq on Friday in a $108m initial public offering that gave exits to pharmaceutical companies Regeneron and Novartis.
Intellia priced six million shares at $18 each on Friday, at the top of the $16 to $18 range it set last month. It also issued a million more shares than the five million it had previously planned.
Founded in 2014 by cellular engineering technology provider Caribou Biosciences, and venture capital…
